Some contend that the pharmaceuticals might eventually conserve funds for healthcare systems by mitigating the likelihood of obesity-related illnesses. However, a recent investigation co-authored by Jason Abaluck from Yale SOM indicates that additional health expenditures, aside from the medication expenses, could indeed rise during the initial few years of treatment.